TG Therapeutics, Inc. (TGTX) shares rose 10.48 percent, gaining $3.84 to $40.48 on Tuesday after the company reported positive pharmacokinetic, pharmacodynamic, safety, and tolerability results from its Phase 1 clinical trial evaluating a subcutaneous formulation of BRIUMVI compared with the currently approved intravenous version.
The stock is currently trading at $40.48, compared with its previous close of $36.64. During the session, it opened at $38.65 and traded between $37.96 and $40.69. Trading volume reached 1.02 million shares.
The company said the proprietary high-concentration, low-volume formulation was well tolerated and achieved sustained drug exposure. Data from the study support the quarterly and every-other-month dosing regimens currently being evaluated in an ongoing Phase 3 trial. Management noted that, if approved, subcutaneous BRIUMVI could become the first self-administered, at-home quarterly anti-CD20 therapy for multiple sclerosis patients.
TG Therapeutics shares have traded between $25.28 and $44.65 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.